Hepatobiliary and pancreatic (HBP) cancers are among the most aggressive malignancies, with recurrence and metastasis driven by tumor heterogeneity and drug resistance, presenting considerable challenges to effective treatment.
Currently, personalized and accurate treatment prediction models for these cancers are lacking.
Patient-derived organoids (PDOs) tumor are three-dimensional
